BIO Stock - Bio-Rad Laboratories, Inc.
Unlock GoAI Insights for BIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B |
| Gross Profit | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B |
| Gross Margin | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% |
| Operating Income | $269.00M | $337.80M | $482.62M | $500.34M | $421.33M |
| Net Income | $-1,844,200,000 | $-637,324,000 | $-3,627,535,000 | $4.25B | $3.81B |
| Net Margin | -71.9% | -23.9% | -129.5% | 145.6% | 149.8% |
| EPS | $-65.36 | $-21.82 | $-121.79 | $142.61 | $127.86 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 1st 2024 | Citigroup | Upgrade | Buy | $400← $350 |
| August 28th 2024 | Wells Fargo | Initiation | Equal Weight | $340 |
| June 3rd 2024 | Jefferies | Resumed | Hold | $315 |
| April 3rd 2024 | Citigroup | Downgrade | Neutral | $365← $400 |
| December 7th 2023 | UBS | Initiation | Buy | $395 |
| June 16th 2023 | Wells Fargo | Initiation | Overweight | $550 |
| December 7th 2022 | RBC Capital Mkts | Initiation | Outperform | $565 |
| August 25th 2022 | Credit Suisse | Initiation | Outperform | $715 |
Earnings History & Surprises
BIOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $2.57 | — | — | — |
Q4 2025 | Oct 29, 2025 | $2.30 | $2.26 | -1.7% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $1.93 | $2.61 | +35.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $1.73 | $2.54 | +46.8% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $2.86 | $2.90 | +1.4% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $1.28 | $2.01 | +57.0% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $2.12 | $3.11 | +46.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $2.15 | $2.29 | +6.5% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $2.93 | $3.10 | +5.8% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $2.87 | $2.33 | -18.8% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $2.55 | $3.00 | +17.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $3.24 | $3.34 | +3.1% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $3.45 | $3.31 | -4.1% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $2.59 | $2.60 | +0.4% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $2.46 | $3.38 | +37.4% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $2.80 | $4.94 | +76.4% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $2.87 | $3.21 | +11.8% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $2.30 | $3.71 | +61.3% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $1.90 | $3.54 | +86.3% | ✓ BEAT |
Latest News
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
📈 PositiveWells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
📈 PositiveCORRECTION: Bio-Rad Laboratories Q3 Adj. EPS $2.26 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate
📈 PositiveBio-Rad Laboratories, Inc. Non-GAAP EPS of $2.26 beats by $0.33, revenue of $653M beats by $1.7M
📈 PositiveBio-Rad Laboratories Affirms FY2025 Sales Guidance of $2.567B-$2.593B vs $2.593B Est
➖ NeutralBio-Rad Laboratories Q3 Adj. EPS $2.20 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate
📈 PositiveBiodesix Expands Partnership With Bio-Rad Laboratories To Develop Droplet Digital PCR High Complexity Oncology Assays On QX600 Platform
📈 PositiveKALA BIO plunges 92% after phase 2 failure of eye condition drug
📉 NegativeFrequently Asked Questions about BIO
What is BIO's current stock price?
What is the analyst price target for BIO?
What sector is Bio-Rad Laboratories, Inc. in?
What is BIO's market cap?
Does BIO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIO for comparison